Assessment of safety and feasibility of non-invasive vagus nerve stimulation for treatment of acute stroke
dc.contributor.author | Arsava, Ethem Murat | |
dc.contributor.author | Topcuoglu, Mehmet Akif | |
dc.contributor.author | Ay, Ilknur | |
dc.contributor.author | Ozdemir, Atilla Ozcan | |
dc.contributor.author | Gungor, Ibrahim Levent | |
dc.contributor.author | Isikay, Canan Togay | |
dc.contributor.author | Nazliel, Bijen | |
dc.date.accessioned | 2024-02-23T14:02:22Z | |
dc.date.available | 2024-02-23T14:02:22Z | |
dc.date.issued | 2022 | |
dc.department | NEÜ | en_US |
dc.description.abstract | Background: Non-invasive vagus nerve stimulation (nVNS) using a hand-held stimulator placed on the neck is an FDA-approved treatment for primary headache disorders. The safety of nVNS is unknown in stroke patients. Objective: To assess the safety and feasibility of nVNS for the acute treatment of stroke. Methods: TR-VENUS (clinicaltrials.gov identifier NCT03733431) was a randomized, sham-controlled, open-label, multicenter trial conducted in patients with acute ischemic stroke (IS) or intracerebral hemorrhage (ICH). Patients were randomly assigned to standard-dose nVNS, high-dose nVNS, or sham stimulation. The primary endpoint was a composite safety outcome defined as bradycardia or reduction in mean arterial blood pressure during treatment or progression of neurological or death within 24 h of treatment. The feasibility endpoints were the proportion of eligible subjects receiving nVNS within 6 h of symptom onset and the proportion completing all pre-specified treatment doses. Efficacy assessments included infarct growth from baseline to 24 h after treatment. Results: Sixty-nine patients (61 IS, 8 ICH) completed the study. The composite safety outcome was achieved in 32.0% in sham and 47.7% in nVNS group (p = 0.203). Treatment was initiated in all but two randomized patients. All dosed subjects received 100% of prespecified stimulations. A non-significant reduction in infarct growth was observed in the high-dose nVNS group (184.2% in sham vs. 63.3% in high-dose nVNS; p = 0.109). Conclusions: The results of this study suggest that nVNS may be safe and feasible in the setting of acute stroke. These findings support further development of nVNS as a potential treatment for acute ischemic stroke. (c) 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). | en_US |
dc.description.sponsorship | Eric Liebler; ElectroCore LLC | en_US |
dc.description.sponsorship | We are thankful to Eric Liebler from ElectroCore LLC for his support during the study. The study was monitored by an independent contract research organization (Monitor CRO, _Istanbul, Turkey). An independent data monitoring committee was responsible for assessing safety outcomes at the interim analysis stage. | en_US |
dc.identifier.doi | 10.1016/j.brs.2022.10.012 | |
dc.identifier.endpage | 1474 | en_US |
dc.identifier.issn | 1935-861X | |
dc.identifier.issn | 1876-4754 | |
dc.identifier.issue | 6 | en_US |
dc.identifier.pmid | 36356829 | en_US |
dc.identifier.scopus | 2-s2.0-85141950507 | en_US |
dc.identifier.scopusquality | Q1 | en_US |
dc.identifier.startpage | 1467 | en_US |
dc.identifier.uri | https://doi.org/10.1016/j.brs.2022.10.012 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12452/11676 | |
dc.identifier.volume | 15 | en_US |
dc.identifier.wos | WOS:000895634600008 | en_US |
dc.identifier.wosquality | Q1 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.indekslendigikaynak | Scopus | en_US |
dc.indekslendigikaynak | PubMed | en_US |
dc.language.iso | en | en_US |
dc.publisher | Elsevier Science Inc | en_US |
dc.relation.ispartof | Brain Stimulation | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Acute Stroke | en_US |
dc.subject | Vagus Nerve | en_US |
dc.subject | Stimulation | en_US |
dc.subject | Safety | en_US |
dc.subject | Randomized Trial | en_US |
dc.title | Assessment of safety and feasibility of non-invasive vagus nerve stimulation for treatment of acute stroke | en_US |
dc.type | Article | en_US |